Nobel Prize in Chemistry 2020 for CRISPR-Cas9 Genetic Scissors

On 7 October 2020, the Royal Swedish Academy of Sciences awarded the Nobel Prize in Chemistry 2020 to Emmanuelle Charpentier and Jennifer A. Doudna for the development of a method for genome editing.  Currently Emmanuelle Charpentier works at the Max Planck Unit for the Science of Pathogens in Berlin, Germany, and Jennifer A. Doudna at the University of California, Berkeley, USA.

Emmanuelle Charpentier and Jennifer A. Doudna; the Awardees for their development of CRISPR-Cas9
Emanuelle Charpentier [1] and Jennifer A. Doudna [2]

Charpentier and team published their initial discovery on bacterial genome editing in 2011[3]. In collaboration with Doudna, they were able to establish and simplify the method[4]. Their discovery and further developments of the CRISPR-Cas9 genetic scissors made one of most powerful technologies for genome editing widely accessible. In essence, Cas9-RNA mediates site-specific genome engineering in the genome of human cells, or other eukaryotes. One of the applications for in-vivo human gene therapy is that the Cas-9 enzyme can be used to reverse undesirable mutations[5], making it possible to treat a wide variety of diseases, including previously untreatable monogenic diseases. Overall, CRISPR-Cas9 technology has a highly transformative potential that is expected to have an impacts on various important megatrends in biotechnology and medicine bringing great benefits to mankind (figure 1).

Current and potential applications of CRISPR-Cas9
Figure 1: Current and potential applications  of CRISPR-Cas9 genome editing. Adapted from [6].

Supertrends: driven by expert insights

Our goal at Supertrends is to raise awareness about the significant scientific, technological, economic and social developments that will shape our future as we know it. Thus, we provide a platform for the voices of the groundbreaking experts, scientists, developers and entrepreneurs across a wide variety of industries. If you think you might be one of them, learn more about becoming a Supertrends expert here. If you’d like to continue reading, you can explore our growing list of article topics featuring Supertrends experts below:

© 2020 Supertrends




[3] Deltcheva, E. et al. 2011. CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature 471(7340):602-7.

[4] Jinek, M., J.A. Doudna, E. Charpentier et al. 2012. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337(6096):816-21.


[6] Doudna, J.A. and E. Charpentier 2014. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science 346(6213):1258096.

CRISPR, CRISPR-Cas9, Gene Editing, Nobel Prize

Frank Staedtler

Frank received his PhD training as molecular biologist and geneticist at the University of Bonn and the Max Planck Institute in Cologne, Germany. During his post-doc at Sandoz he certified as toxicologist and started his career in preclinical pharmaceutical drug safety in Switzerland. At Novartis he had various scientific matrix and line-function leadership roles at the translational interface between R&D. His roles focused on biomarkers of safety, efficacy, or disease and technologies for human genome analysis. At Roche and the University Hospital of Zurich lead and applied Next-Generation-Sequencing for tumor diagnostics with the goal to reveal targeted treatment options for cancer patients, a precision medicine approach. Currently Frank works as Senior Clinical Scientist for another start-up company developing a diagnostic assay for early cancer detection. In his role as Editor & Expert Relationship Manager at Supertrends AG he is interested in all major innovative technologies and trends in the life sciences arena. He likes outdoor leisure and wild-life biology.

Join us


Sign up for our Newsletter


Supertrends AG, Erlenstrasse 16, 6300 Zug